newsfilter
← Latest News
PR Newswire·

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

  • TuHURA Biosciences reported financial results for the third quarter ended September 30, 2026, and provided corporate updates on its immuno-oncology programs.
  • Preliminary data from an open-label study of IFx-2.0 combined with Keytruda showed durable major objective anti-tumor responses in the first three patients with metastatic Merkel cell carcinoma, with all responses ongoing for over six months.
  • The FDA granted clearance to begin a Phase 1b study of TBS-2025, a VISTA-inhibiting antibody, in patients with relapsed/refractory mut NPM1 acute myeloid leukemia.
  • TuHURA announced three poster presentations at the upcoming American Society of Hematology Annual Meeting in December 2026 to highlight Delta Opioid Receptor technology.
  • The company received a new U.S. patent for TBS-2025 extending coverage to bispecific antibodies across all human antibody classes with a term through 2042.
  • A key U.S. patent was received for Delta Opioid Receptor antibody drug conjugate technology, covering uses in adoptive cellular immunotherapies with a term through 2043.
  • The company secured $5.6 million in non-dilutive financing from the Parkview loan facility during the quarter, bringing total gross proceeds on the facility to $9.2 million.
  • Cash and cash equivalents stood at $1.9 million as of September 30, 2026.
  • Research and development expenses decreased to $3.7 million from $5.0 million in the prior year quarter due to lower manufacturing costs.
  • General and administrative expenses increased to $2.0 million from $1.6 million in the prior year quarter, driven by non-cash stock compensation costs.
  • Anticipated milestones include receiving orphan drug designation for IFx-2.0 in the second half of 2026 and initiating the Phase 1b/2 trial for TBS-2025 in the same period.
  • TuHURA remains a Phase 3 immuno-oncology company focused on overcoming resistance to cancer immunotherapy through its IFx-2.0, TBS-2025, and Delta Opioid Receptor programs.
Company
TuHURA Biosciences, Inc.
Keywords
TuHURA Biosciences, Inc.